© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
January 30, 2023
Switching their focus to transplant-ineligible multiple myeloma, panelists review available triplet therapy regimens for induction therapy.
A brief discussion how to select the appropriate treatment strategy in transplant-eligible newly diagnosed myeloma and whether there is a role for minimal residual disease in assessing response and treatment duration.
January 20, 2023
In light of recent clinical trial data, key opinion leaders reflect on the appropriate selection of transplant for patients with newly diagnosed multiple myeloma.
Opening discussion on the management of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider the role of quadruplet therapy and transplant in this setting.